Sector News

With GSK swap behind it, Novartis scouts for $2B-$5B buyouts

April 23, 2015
Life sciences
A little more than a month after completing its big asset swap with GlaxoSmithKline, Novartis CEO Joe Jimenez says he’s going back to the bargaining table to look for some bolt-on buyouts in the $2 billion to $5 billion range.
 
“We’ve put our M&A people back to work,” Jimenez told reporters this morning, according to a report from Bloomberg. Novartis is looking past an expected approval for the heart drug LCZ696 as it scouts for new therapies that can remedy a painful loss of franchise cash to generic competition.
 
In its deal with GSK, Novartis handed over a portfolio of underperforming vaccine assets in exchange for Glaxo’s less-than-compelling cancer drug portfolio. Each of the pharma giants expects to do better by concentrating their focus on core assets.
 
For Novartis, that’s meant forming a new immuno-oncology division in Cambridge, MA, under former Dana Farber researcher Glenn Dranoff. Just weeks ago Novartis executed a $750 million tie-up with Aduro–a deal that Jimenez noted today “strengthens our presence in immuno-oncology.” And Jimenez has been an eager advocate of a growing CAR-T research operation at the University of Pennsylvania, which is reengineering T cells into cancer cell killers.
 
The CEO’s comments will do nothing to calm the frenzied expectations for more M&A in the coming months. Like just about everybody in Big Pharma, with the possible exception of Pfizer, Novartis is shunning big buyouts after a full slate of high-end mergers delivered little in the way of sustainable growth or appreciable pipeline value. The focus on new assets in the under-$10 billion category has helped swell valuations across the board in biotech. 
 
While the swap with GSK may be officially completed, there’s still a significant amount of fallout expected among rank and file staffers. While largely applauded by Wall Street, a swap like this can trigger big layoffs, as GSK has demonstrated with plans to centralize its vaccine division in Rockville, MD, while uprooting organizations in Philadelphia and Boston with hundreds of employees. Novartis has yet to reveal how it plans to integrate its new oncology assets into the company, but pink slips are likely.
 
By John Carroll
 

Related News

June 19, 2021

P&G-backed Kindra to tap into overlooked menopause sector after landing US$4.5M

Life sciences

Kindra has closed a US$4.5 million seed funding round to expand and grow its menopause offerings. The US-based brand, which is backed by P&G Ventures, aims to drive a cultural shift around menopause, which has been “long overlooked.”

June 19, 2021

Johnson & Johnson among companies excluding Colorado residents from remote job openings after new state law

Life sciences

Colorado established a new law this year requiring companies to divulge a salary range on job postings. But some large companies, like Johnson & Johnson, McKesson and Cardinal Health, have responded by barring candidates from the state.

June 19, 2021

Former Emisphere investors sue over ‘ill-timed’ $1.8B sale to Novo Nordisk

Life sciences

Former Emisphere stockholder IsZo Capital is one of several parties seeking damages against controlling stockholder MHR Fund Management for allegedly “co-opting” the drug delivery specialist’s board and forcing an “ill-timed” sale to Novo Nordisk at an “artificially low price,” a new lawsuit says.

Send this to a friend